Panmira is the Amira pre-acquisition spin-out of the DP2 asset. Panmira formally started business at the beginning of September after splitting from Amira at the time of Amira’s acquisition by Bristol Myers Squibb. The company was provided with $5M from Amira to fund its operations. The company had eight employees at the inception.
Panmira’s mission was to partner the assets that it acquired from Amira namely the CRTH2 program (containing two clinical phase compounds; AM211 and AM461), a FLAP compound for topical use (AM679) and a preclinical lead for 5-LO. Panmira downsized the operations to three employees and out-sourced all other activities.